325 related articles for article (PubMed ID: 26596782)
1. The Bromodomain: A New Target in Emerging Epigenetic Medicine.
Smith SG; Zhou MM
ACS Chem Biol; 2016 Mar; 11(3):598-608. PubMed ID: 26596782
[TBL] [Abstract][Full Text] [Related]
2. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins.
Taniguchi Y
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827996
[TBL] [Abstract][Full Text] [Related]
3. BET Bromodomain as a Target of Epigenetic Therapy.
Noguchi-Yachide T
Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
[TBL] [Abstract][Full Text] [Related]
4. Targeting bromodomains: epigenetic readers of lysine acetylation.
Filippakopoulos P; Knapp S
Nat Rev Drug Discov; 2014 May; 13(5):337-56. PubMed ID: 24751816
[TBL] [Abstract][Full Text] [Related]
5. Bromodomains: Structure, function and pharmacology of inhibition.
Ferri E; Petosa C; McKenna CE
Biochem Pharmacol; 2016 Apr; 106():1-18. PubMed ID: 26707800
[TBL] [Abstract][Full Text] [Related]
6. Bromodomain inhibitors and cancer therapy: From structures to applications.
Pérez-Salvia M; Esteller M
Epigenetics; 2017 May; 12(5):323-339. PubMed ID: 27911230
[TBL] [Abstract][Full Text] [Related]
7. Bromodomains: Translating the words of lysine acetylation into myelin injury and repair.
Ntranos A; Casaccia P
Neurosci Lett; 2016 Jun; 625():4-10. PubMed ID: 26472704
[TBL] [Abstract][Full Text] [Related]
8. Bromodomains and their pharmacological inhibitors.
Gallenkamp D; Gelato KA; Haendler B; Weinmann H
ChemMedChem; 2014 Mar; 9(3):438-64. PubMed ID: 24497428
[TBL] [Abstract][Full Text] [Related]
9. Targeting the epigenetic reader "BET" as a therapeutic strategy for cancer.
Wahi A; Manchanda N; Jain P; Jadhav HR
Bioorg Chem; 2023 Nov; 140():106833. PubMed ID: 37683545
[TBL] [Abstract][Full Text] [Related]
10. Emerging tools to investigate bromodomain functions.
Kougnassoukou Tchara PE; Filippakopoulos P; Lambert JP
Methods; 2020 Dec; 184():40-52. PubMed ID: 31726225
[TBL] [Abstract][Full Text] [Related]
11. The BRD3 ET domain recognizes a short peptide motif through a mechanism that is conserved across chromatin remodelers and transcriptional regulators.
Wai DCC; Szyszka TN; Campbell AE; Kwong C; Wilkinson-White LE; Silva APG; Low JKK; Kwan AH; Gamsjaeger R; Chalmers JD; Patrick WM; Lu B; Vakoc CR; Blobel GA; Mackay JP
J Biol Chem; 2018 May; 293(19):7160-7175. PubMed ID: 29567837
[TBL] [Abstract][Full Text] [Related]
12. Effect of BET Missense Mutations on Bromodomain Function, Inhibitor Binding and Stability.
Lori L; Pasquo A; Lori C; Petrosino M; Chiaraluce R; Tallant C; Knapp S; Consalvi V
PLoS One; 2016; 11(7):e0159180. PubMed ID: 27403962
[TBL] [Abstract][Full Text] [Related]
13. BET bromodomain inhibitors show anti-papillomavirus activity in vitro and block CRPV wart growth in vivo.
Morse MA; Balogh KK; Brendle SA; Campbell CA; Chen MX; Furze RC; Harada IL; Holyer ID; Kumar U; Lee K; Prinjha RK; Rüdiger M; Seal JT; Taylor S; Witherington J; Christensen ND
Antiviral Res; 2018 Jun; 154():158-165. PubMed ID: 29653131
[TBL] [Abstract][Full Text] [Related]
14. Selective recognition of acetylated histones by bromodomains in transcriptional co-activators.
Hassan AH; Awad S; Al-Natour Z; Othman S; Mustafa F; Rizvi TA
Biochem J; 2007 Feb; 402(1):125-33. PubMed ID: 17049045
[TBL] [Abstract][Full Text] [Related]
15. Bromodomain: an acetyl-lysine binding domain.
Zeng L; Zhou MM
FEBS Lett; 2002 Feb; 513(1):124-8. PubMed ID: 11911891
[TBL] [Abstract][Full Text] [Related]
16. BET-Family Bromodomains Can Recognize Diacetylated Sequences from Transcription Factors Using a Conserved Mechanism.
Patel K; Solomon PD; Walshe JL; Ford DJ; Wilkinson-White L; Payne RJ; Low JKK; Mackay JP
Biochemistry; 2021 Mar; 60(9):648-662. PubMed ID: 33620209
[TBL] [Abstract][Full Text] [Related]
17. Tandem bromodomains in the chromatin remodeler RSC recognize acetylated histone H3 Lys14.
Kasten M; Szerlong H; Erdjument-Bromage H; Tempst P; Werner M; Cairns BR
EMBO J; 2004 Mar; 23(6):1348-59. PubMed ID: 15014446
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence.
Chaidos A; Caputo V; Karadimitris A
Ther Adv Hematol; 2015 Jun; 6(3):128-41. PubMed ID: 26137204
[TBL] [Abstract][Full Text] [Related]
19. An Activity-Based Probe Targeting Non-Catalytic, Highly Conserved Amino Acid Residues within Bromodomains.
D'Ascenzio M; Pugh KM; Konietzny R; Berridge G; Tallant C; Hashem S; Monteiro O; Thomas JR; Schirle M; Knapp S; Marsden B; Fedorov O; Bountra C; Kessler BM; Brennan PE
Angew Chem Int Ed Engl; 2019 Jan; 58(4):1007-1012. PubMed ID: 30589164
[TBL] [Abstract][Full Text] [Related]
20. Chemical Epigenetics: The Impact of Chemical and Chemical Biology Techniques on Bromodomain Target Validation.
Schiedel M; Moroglu M; Ascough DMH; Chamberlain AER; Kamps JJAG; Sekirnik AR; Conway SJ
Angew Chem Int Ed Engl; 2019 Dec; 58(50):17930-17952. PubMed ID: 30633431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
